Bank of America Global Healthcare Conference 2026
Logotype for Kestra Medical Technologies Limited

Kestra Medical Technologies (KMTS) Bank of America Global Healthcare Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Kestra Medical Technologies Limited

Bank of America Global Healthcare Conference 2026 summary

14 May, 2026

Business momentum and market dynamics

  • Achieved strong momentum in FY 2026, driven by securing over 70% payer contract coverage and expanding the sales force from 80 to 130 reps, resulting in increased productivity and market penetration.

  • Market growth for WCDs is robust, with the overall market expanding at 14% and the company achieving 60% growth in the last quarter, outpacing competitors.

  • Market share in covered territories exceeds 25-30%, with top reps reaching over 70% share in mature accounts.

  • The addressable market remains underpenetrated, with only one in seven eligible patients prescribed a WCD, suggesting significant runway for growth over the next five years.

  • Expansion into new territories is data-driven, focusing on high-prescriber areas with payer coverage, and supported by clinical specialists to accelerate account development.

Sales force strategy and productivity

  • Sales force expansion is carefully targeted, often splitting high-performing territories to maximize coverage and productivity without cannibalizing existing business.

  • New reps ramp up to 10 fittings per month within six months, with top performers exceeding 50 fittings monthly, surpassing initial productivity models.

  • Clinical specialists are added to support high-performing reps, further accelerating growth in established accounts.

  • Investments in direct-to-cardiology sales and resource allocation are guided by ZIP code-level data on fittings and insurance coverage.

Clinical data, guidelines, and innovation

  • The ACE-PAS post-approval study of 21,000 patients has been well received, providing strong evidence for WCD use and helping to dispel competitor myths.

  • New clinical data is expected to drive guideline upgrades from 2B to 2A, potentially doubling or tripling the eligible patient base within a few years.

  • Recent algorithm upgrades have halved false alarm rates and reduced inappropriate shocks by over 60%, further differentiating the product.

  • Ongoing innovation is planned across electronics, wearable, and digital platforms, with new product launches expected annually.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more